All Companies


Acceleron Pharma Inc [XLRN] US$2,277 MM MCap
Lead ther­a­peu­tic can­di­date in he­ma­tol­o­gy, lus­pa­ter­cept, un­der a glob­al part­n­er­ship with Cel­gene, re­port­ed pos­i­tive Phase 3 ME­DAL­IST and BE­LIEVE trial re­sults, and cont­in­ues to ad­vance mul­ti­ple Ph2 and Ph3 trials for the treat­ment of chron­ic ane­mia in myelodys­plas­tic syn­dromes, be­ta-tha­lassemia, and myelo­fi­bro­sis. [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. [ACRX] US$200 MM MCap
Re­cent­ly launched DSU­VIA; rev-gen­er­at­ing in Q1. Plans to re­sub­mit Za­lvi­so NDA in US by YE [more in­for­ma­tion]
Adverum Biotechnologies [ADVM] US$399 MM MCap
Oc­u­lar / rare dis­ease gene thx. AD­VM-022 in P1 OP­TIC study in wAMD. 24-wk da­ta co­hort 1 (6 pts) pre­sent­ed in Septem­ber, 52-week da­ta from co­hort 1 and 24-week da­ta from co­hort 2 exp. 1H20. Col­lab­o­ra­tions in place with Re­generon and Ed­i­tas. [more in­for­ma­tion]
Affibody
Pro­pri­e­tary Af­fi­body® molecules and Al­bu­mod plat­forms. 4 clin­i­cal / late-stage, pro­pri­e­tary pro­grams in­clud­ing pso­ri­a­sis, B-cell au­toim­mune dis­eas­es, & liv­er dis­eas­es. Pipe­line al­so in­cludes Dx imag­ing pro­gram tar­get­ing me­tastat­ic breast can­cer. [more in­for­ma­tion]
Affimed N.V. [AFMD] US$227 MM MCap
NK cell en­gager AFM13 (CD30/CD16A) that is poised to en­ter a Phase 2 reg­is­tra­tion study in CD30-pos­i­tive pe­ripher­al T cell lym­pho­ma and an in­vesti­ga­tor-spon­sored study by MDACC of AFM13 com­bined with al­lo­gene­ic NK cells in re­lapsed/re­frac­to­ry CD30-pos­i­tive lym­pho­ma. Af­fimed al­so plans to file an IND in the third quar­ter of 2019 for AFM24, the com­pany’s in­nate cell en­gager that tar­gets EGFR-ex­press­ing solid tu­mors. [more in­for­ma­tion]
Aileron Therapeutics, Inc. [ALRN] US$26 MM MCap
Clin­i­cal stage on­col­o­gy com­pany con­duct­ing 3 clin­i­cal trials for its lead can­di­date, AL­RN-6924, a first-in-class/best-in-class drug that tar­gets the p53 path­way. AL­RN-6924 is from the Sta­pled pep­tide plat­form and is the on­ly clin­i­cal drug can­di­date that binds equipo­tent­ly to both of the p53 sup­pres­sor pro­teins, MD­MX and MD­M2. [more in­for­ma­tion]
AM-Pharma B.V.
[more in­for­ma­tion]
Amarin Corporation [AMRN] US$6,051 MM MCap
Vas­ce­pa: 1st and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in adults. Pre­sent­ed (+) da­ta from RE­DUCE-IT CV Out­comes trial at AHA [more in­for­ma­tion]
Antev
Ph3 ready hor­mone ther­a­py com­pany with an in­jectable, long-act­ing GnRH an­ta­g­on­ist for pros­tate can­cer and be­nign pro­stat­ic hy­per­pla­sia. An in­jectable en­ables ex­tend­ed drug ac­tiv­i­ty, which is im­por­tant for in­di­ca­tions with ac­tive oral an­ta­g­on­ists in late-stage de­vel­op­ment and al­so ap­proved agent(s). The safe­ty pro­file looks good with over 415 sub­jects dosed over 805 times. [more in­for­ma­tion]
Apexigen
CD40 ag­on­ist mAb; 170+ pts dosed (mono & com­bi sett­ings). 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. AACR: Ph 1b da­ta (w/Park­er Inst); col­labs w/BMY, MDACC, Yale, et al [more in­for­ma­tion]
Aptorum Group [APM] US$489 MM MCap
Ap­to­rum is a phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to de­vel­op­ing and com­mer­cial­iz­ing a broad range of ther­a­peu­tic and di­ag­nos­tic tech­nolo­gies to tack­le un­met med­i­cal needs. Ap­to­rum is pur­su­ing ther­a­peu­tic and di­ag­nos­tic pro­jects in neu­rol­o­gy, in­fec­tious dis­eas­es, gas­troen­terol­o­gy, on­col­o­gy and other dis­ease ar­eas; [more in­for­ma­tion]
Arcellx
Cur­rent en­gi­neered im­mune cell ther­a­pies of­ten tar­get tu­mors through a mono-spe­cif­ic re­cep­tor that is con­sti­tu­tive­ly ex­pressed and ac­tive. In con­trast, Ar­cel­lx has de­vel­oped Anti­gen Re­cep­tor Com­plex T cells (ARC-T) that are read­i­ly si­lenced, ac­ti­vat­ed, and re­pro­grammed in vi­vo by ad­min­is­tra­tion of a tu­mor-tar­get­ing anti­gen pro­tein called a sparX. [more in­for­ma­tion]
AsclepiX Therapeutics
AX­T107 de­mon­s­trat­ed ef­fi­ca­cy and dura­bil­i­ty in rab­bit and mouse mod­els that is su­pe­ri­or to stan­dard of care Eye­lea. [more in­for­ma­tion]
Asklepion Pharmaceuticals
Pri­vate, fo­cused on the de­vel­op­ment of IV Cit­rul­line for rare pe­di­a­tric dis­eas­es. First in­di­ca­tion, the pre­ven­tion of sig­ni­f­i­cant se­que­lae of pe­di­a­tric acute car­diopul­mo­nary by­pass-in­duced lung in­jury, Ph 3 trial is on­go­ing. [more in­for­ma­tion]
Assembly Biosciences, Inc. [ASMB] US$381 MM MCap
The mi­cro­biome pro­gram is de­vel­op­ing nov­el oral live mi­cro­bial bio­ther­a­peu­tic can­di­dates with As­sem­b­ly’s ful­ly in­te­grat­ed plat­form, in­clud­ing a ro­bust pro­cess for strain iden­ti­fi­ca­tion and se­lec­tion, GMP bank­ing and pro­duc­tion, and tar­get­ed de­liv­ery to the low­er gas­troin­testi­nal tract with the GEMI­CEL® tech­nol­o­gy. [more in­for­ma­tion]
Avacta [AVCT:LN] £24 MM MCap
Avac­ta is ad­dress­ing this need and build­ing a clin­i­cal­ly dif­fer­en­ti­at­ed pipe­line by com­bin­ing its two pro­pri­e­tary plat­forms – Af­fimers®, a best-in-class anti­body mimet­ic, and tu­mour tar­get­ed che­mother­a­pies that syn­er­gise with Af­fimer check­point mo­d­u­la­tors. [more in­for­ma­tion]
AxoGen [AXGN] US$549 MM MCap
Da­m­age or tran­sec­tion to pe­ripher­al nerves. Q1 revs $23.3M, 35% growth YoY; exp 2019 rev bt $109-$114M [more in­for­ma­tion]
Bavarian Nordic A/S [BVNRY] US$876 MM MCap
Vaccines for in­fec­tious dis­eas­es and on­col­o­gy. Can­cer vaccines in com­bo with mul­ti­ple check­point in­hibi­tors (Roche/Mer­ck/BMS). Uni­ver­sal RSV vaccine with pos­i­tive phase 2 da­ta. Re­cent con­tract from US Gov. for small­pox vaccine val­ued at over $500M. Part­n­er­ship with JNJ for vaccines against HIV/HBV/HPV with over $1B in po­ten­tial mile­s­tones. [more in­for­ma­tion]
Bellicum Pharmaceuticals Inc. [BLCM] US$51 MM MCap
Molec­u­lar switch tech­nol­o­gy and co-stim do­mains en­ables phar­ma­co­log­ic con­trol over cells for en­hanced ef­fi­ca­cy and safe­ty. Lead (reg­is­tra­tio­n­al EU) pro­gram: Ph2 for ri­vo-cel (al­pha/be­ta ad­d­back T-cell ther­a­py for post al­lo­gene­ic HSTC in non-ma­lig­nant and ma­lig­nant dis­eas­es). Pos­i­tive late in­ter­im anal­y­sis on ri­vo-cel exp at ASH 2018; [more in­for­ma­tion]
Bellus Health [BLU:CA] Can$535 MM MCap
BEL­LUS' lead prod­uct can­di­date, BLU-5937, is be­ing de­vel­oped for the treat­ment of chron­ic cough (Phase II an­nounced Ju­ly 2020) and chron­ic pru­ri­tus (Phase II planned to be­gin 1H20). [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr900 MM MCap
De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) in four com­pany-spon­sored trials. [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] US$2,487 MM MCap
Pre­sent­ed ex­pand­ed da­ta at AHS (Ju­ly 2019) /dosed 1,780+ pa­tients (com­bined ex­po­sure of 105k dos­es) and ex­pand­ed safe­ty & pre­lim pre­ven­tive ef­fi­ca­cy da­ta (May 2019) from long-term safe­ty study. Up­com­ing mile­s­tones: Ph 3 to­p­line da­ta in pre­ven­tive treat­ment of mi­graine (rimege­pant) & Ph 2/3 to­p­line ef­fi­ca­cy & safe­ty in in­tra­nasal (BHV-3500) for acute treat­ment of mi­graine in 4Q19. [more in­for­ma­tion]
BioPharmX [BPMX] US$5 MM MCap
De­vel­op­ing BPX-04 for rosacea, us­ing pro­pri­e­ta­ty hy­drophil­ic top­i­cal for­mu­la­tion tech­nol­o­gy. En­rolling Ph2b w da­ta exp in 2019. Com­plet­ed Ph 2b with BPX-01 in acne. [more in­for­ma­tion]
BrainStorm Cell Therapeutics Inc. [BCLI] US$91 MM MCap
NurOwn® au­tol­o­gous cell ther­a­py plat­form for neu­rode­gen­er­a­tive dis­eas­es. Lead can­di­date for ALS, Ph2 eval­u­at­ed 60 ALS pts w fa­vor­able safe­ty/tol­er­a­bil­i­ty. Ph3 cur­rent­ly en­rolling 200 pts across 6 US cen­ters; top-line da­ta ex­pect­ed in mid-2020. Phase 2 trial in pro­gres­sive MS on­go­ing at Cleve­land Clin­ic and Stan­ford Uni­ver­si­ty - to­p­line da­ta mid-2020. [more in­for­ma­tion]
CAI International, Inc. [CAI] US$396 MM MCap
CAI (NYSE: CAI) is a glob­al tran­s­por­ta­tion com­pany of­fer­ing in­ter­mo­dal con­tain­er leas­ing and sales, rail leas­ing and op­er­a­tions, and glob­al lo­gis­tics ser­vices. Estab­lished in 1989 and head­quar­tered in San Fran­cis­co, CAI has grown in­to a lead­ing ex­pert in in­ter­mo­dal tran­s­por­ta­tion, in­ter­na­tio­n­al ship­ping, and con­tain­er sales and leas­ing. [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] US$311 MM MCap
NM­PA re­view in progress for ZE­VALIN® and MAR­QI­BO® (in-li­censed from Spec­trum). Re­cent­ly (2Q19) acq'd ex­clu­sive WW rights to com­mer­cial­ize an­ti-CD19 T-cell ther­a­py (CNC­T19) in Chi­na as well as ex­clu­sive WW rights to nov­el an­ti-CD38 mAb (CID-103). Acq'd 25 US FDA-ap­proved AN­DAS from San­doz in Jan 2018. [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. [CPRX] US$676 MM MCap
Fir­dapse ap­proved 11/18, Q1 sales of $12m: 380 ac­tive LEMS pa­tients on ther­a­py (a/o May 9) [more in­for­ma­tion]
Cellular Biomedicine Group, Inc. [CBMG] US$287 MM MCap
Vali­dates CB­MG's in-house cell man­u­fac­tur­ing ca­pa­bil­i­ties de­vel­oped in part­n­er­ship with Gen­er­al Elec­tric and Ther­mo Fish­er. CB­MG's pro­pri­e­tary im­muno-on­col­o­gy pipe­line in­cludes BC­MA, CD22, TCR-T for HCC and TIL for the treat­ment of NS­CLC and other solid tu­mors. [more in­for­ma­tion]
CureVac AG
Found­ing Co of mR­NA space (last round $1bn+). In­tra­tu­mo­ral ther­a­py Ph1 (mul­ti­ple onc in­di­ca­tions) ini­ti­at­ed Q4 17, ear­ly da­ta rep at SITC. First pt en­rolled Ph 1 pro­phy­lac­tic mR­NA ra­bies vax Oct 2018. Pro­phy­lac­tic in­fluen­za vax ini­ti­a­tion Ph 1 2020, OTC de­fi­cien­cy Ph 1 ini­ti­a­tion H219. In­ter­im da­ta /all trials: 2019. [more in­for­ma­tion]
Enzo Biochem, Inc. [ENZ] US$168 MM MCap
$100m revs in F18. Pi­oneer in molec­u­lar di­ag­nos­tics (Dx), lead­ing con­ver­gence of clin­i­cal lab­o­ra­to­ries, life sci­ences and IP through de­vt of unique Dx plat­form tech­nolo­gies pro­vid­ing nu­mer­ous ad­van­tages over pre­vi­ous stan­dards. [more in­for­ma­tion]
ESSA Pharma Inc. [EPIX] US$59 MM MCap
ES­SA Phar­ma Inc is a pre­clin­i­cal stage phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment of small molecule drugs for the treat­ment of cas­tra­tion-re­sis­tant pros­tate can­cer. [more in­for­ma­tion]
Evofem Biosciences, Inc. [EVFM] US$245 MM MCap
Se­cured $30M strate­g­ic in­vest­ment from PDL Bio­S­ciences (PDLI) in April 2019 for 6.7M shares at $4.50 (26% pre­mi­um to pri­or day close) and 25% war­rant cov­er­age. [more in­for­ma­tion]
Forbius
Se­lec­tive in­hibi­tors of TGF Be­ta & EGFR path­ways. AACR: (+) Ph 1 da­ta. 3 on­go­ing Ph 2 trials (SCCHN, NS­CLC, TN­BC); ad­dl Ph 1 trials in IO, Sys­temic Scle­ro­sis & Myelo­fi­bro­sis [more in­for­ma­tion]
Genfit SA [GNFTF] US$653 MM MCap
$155m Mar 2019 US IPO; FDA BTD for Ela­fi­branor (4/19); (+) 36-mo DSMB rec for cont­in­u­a­tion of Ph 3 study in NASH; da­ta by YE [more in­for­ma­tion]
GenSight Biologics [SIGHT:PA] €34 MM MCap
Gene ther­a­py: reti­nal & CNS de­gen­er­a­tive patholo­gies and mi­to­chon­drial dis­ease. Fil­ing for MAA exp Q1 2020 in EU and Q4 2020 in US. Op­to­ge­net­ic pro­gram and tar­get­ed dis­ease im­me­di­ate­ly trans­fer­able to dry AMD. Plat­form com­bines mono-ge­net­ic ther­a­py-based ap­proach w core tech­nol­o­gy plat­form and pro­pri­e­tary Mi­to­chon­drial Tar­get­ing Se­quence. [more in­for­ma­tion]
HaemaLogiX
I-O; nov­el tgts in Mul­ti­ple Myelo­ma (col­lab w Take­da). Kap­paMab (MM) Ph 2b, da­ta 1H20. Kap­paMab Car-T en­ter­ing clin­ic 2019. Kap­paMab & Lamb­daMab tar­get cell sur­face pro­teins KMA and LMA on ab­nor­mal plas­ma cells. Kap­paMab: com­plete & par­tial re­spons­es in Ph 1 & 2a. Kap­pa-mab Car-T en­ter­ing clin­ic 2019. [more in­for­ma­tion]
Hutchison China MediTech Ltd ("Chi-Med") [HCM] US$2,696 MM MCap
Chi-Med has a port­fo­lio of 9 drugs in clin­i­cal de­vel­op­ment from own dis­cov­ery en­gine in its In­no­va­tion plat­form and a cash gen­er­at­ing Com­mer­cial plat­form with 2,500+ sales reps. Glob­al col­lab­o­ra­tion with As­traZene­ca in two reg­is­tra­tion en­abling studies with savol­i­tinib in Ta­gris­so re­frac­to­ry lung can­cer that is MET+ and EGFRm+ (glob­al) and MET Ex­on 14 dele­tion NS­CLC (Chi­na). [more in­for­ma­tion]
Idera Pharmaceuticals, Inc. [IDRA] US$82 MM MCap
Lead can­di­date Til­so­toli­mod (TLR 9 ag­on­ist) used in comb w Ipi in PD1 re­frac­to­ry me­lano­ma pts. En­rolling ad­dl pts in Ph 2 ex­pan­sion and Phase 3 en­roll­ment ex­pect­ed to com­plete Q4 2019. Com­bo of ipi and Til­so­toli­mod ap­pears to ac­ti­vate im­mune re­sponse in pts who have ex­haust­ed all op­tions, e.g. PD1/CPIs. Fast Track des for Til­so­toli­mod (Nov’17). [more in­for­ma­tion]
Inspirion Delivery Sciences LLC
Mor­phaBond ER™ US com­mer­cial launch Nov 2017 (FDA-ap­proved, first sin­gle-en­ti­ty abuse de­ter­rent ER mor­phine prod­uct) and Rox­y­Bond™ (FDA ap­proved, first and on­ly IR abuse-de­ter­rent opi­oid prod­uct) both li­censed to Daiichi Sankyo, Inc. Nov­el ex­tend­ed and im­me­di­ate re­lease tech­nolo­gies en­able pain med­i­ca­tions with abuse de­ter­rent fea­tures, ad­dress­ing the Opi­oid epi­dem­ic. [more in­for­ma­tion]
Iovance Biotherapeutics [IOVA] US$2,566 MM MCap
Late-stage cell ther­a­py com­pany uti­l­iz­ing pro­pri­e­tary au­tol­o­gous tu­mor in­fil­trat­ing lym­pho­cytes (TILs) to at­tack solid tu­mors. The com­pany is con­duct­ing piv­o­tal stage trials in me­tastat­ic me­lano­ma and ad­vanced cer­vi­cal can­cer with BLAs ex­pect­ed 2020. [more in­for­ma­tion]
Kadmon Holdings, Inc. [KDMN] US$350 MM MCap
Plat­form of ROCK in­hibi­tors. ROCK2 in­hibi­tor in reg­is­tra­tion trial cGVHD; en­roll­ment com­ple­tion exp 2H19; ini­tial anal­y­sis exp YE. Ph 2 ini­ti­a­tion in scle­ro­der­ma exp in 2019. [more in­for­ma­tion]
Kineta Inc.
Kine­ta (Pri­vate) is fo­cused on in­nate im­mu­ni­ty and im­munol­o­gy. Signed 2 large ear­ly stage part­ner­ing deals in 2018 - $520M deal with Pfiz­er for its small molecule RIG-I im­munother­a­py and a $360M+ deal with Ge­nen­tech for KCP506, a pre­clin­i­cal, non-opi­oid for chron­ic pain. LHF-535 in Ph 1 for Las­sa Fev­er (fund­ed by Well­come Trust, eli­gi­ble for PRV). [more in­for­ma­tion]
Landos Biopharma
Lan­dos has iden­ti­fied Lan­thio­nine Syn­the­tase C-Like 2 (LAN­CL2) as a nov­el ther­a­peu­tic tar­get for au­toim­mune dis­eas­es, in­clud­ing in­flam­ma­to­ry bow­el dis­ease (IBD); Based on ex­ten­sive pre­clin­i­cal studies, Lan­dos has vali­dat­ed a unique mech­anism of ac­tion in­volv­ing LAN­CL2 that ex­erts po­tent an­ti-in­flam­ma­to­ry ef­fects with an out­s­tand­ing safe­ty pro­file. [more in­for­ma­tion]
Lineage Cell Therapeutics [LCTX] US$157 MM MCap
Cur­rent­ly has 3 clin­i­cal pro­grams: (i) OpRe­gen®, a reti­nal pig­ment epithe­li­um tran­s­plant ther­a­py in Ph 1/2a de­vel­op­ment for dry AMD; ii) OPC1, an oli­go­den­dro­cyte pro­gen­i­tor cell ther­a­py in Ph 1/2a de­vel­op­ment for acute spi­nal cord in­juries; and (iii) VAC2, an al­lo­gene­ic can­cer im­munother­a­py of anti­gen-pre­sent­ing den­drit­ic cells cur­rent­ly in Ph 1 for NS­CLC. [more in­for­ma­tion]
Marker Therapeutics [MRKR] US$273 MM MCap
A clin­i­cal-stage im­muno-on­col­o­gy com­pany with the po­ten­tial to sig­ni­f­i­cant­ly dis­rupt the cur­rent cell ther­a­py land­s­cape. Mark­er's cur­rent Mul­ti­TAA cell ther­a­py is look­ing to ini­ti­ate a Phase II study in AML in 2019. Ad­di­tio­n­al­ly, TPIV200, a T-cell vaccine is cur­rent­ly in Phase 2 for ovarian can­cer and tri­ple-neg­a­tive breast can­cer. [more in­for­ma­tion]
Medigene AG [MDG1:DB] €165 MM MCap
blue­bird bio col­lab; BLUE ini­ti­at­ing trial w/MDG MAGEA-4 can­di­date in 2020. TCRs tar­get­ing HA-1 & MAGE-A1 in de­vt. . DC vax in on­go­ing Ph 1/2; fi­nal read­out in 2019. [more in­for­ma­tion]
Medivir AB [MVIR B:ST] SKr936 MM MCap
Me­di­vir is a phar­ma­ceu­ti­cal com­pany fo­cus­ing on the de­vel­op­ment and com­mer­cial­iza­tion of in­no­va­tive treat­ments for can­cer. To do this ef­fi­cient­ly and with a high suc­cess rate, Me­di­vir brings to­gether a unique com­bi­na­tion of clin­i­cal de­vel­op­ment skills, a col­lab­o­ra­tive cul­ture and an ex­ten­sive in­dus­try ex­pe­ri­ence, with a bal­anced pro­ject port­fo­lio. [more in­for­ma­tion]
Minoryx Therapeutics
Mi­no­ryx is a clin­i­cal stage biotech com­pany lead­ing the de­vel­op­ment of new ther­a­pies for X-ALD and other Or­phan CNS dis­eas­es, a group of rare dis­eas­es of ge­net­ic ori­gin with a high un­met med­i­cal need. [more in­for­ma­tion]
Neoleukin Therapeutics [NLTX] US$94 MM MCap
Re­cent­ly went public through merg­er with Aqui­nox. De­sign­ing de no­vo pro­tein im­munother­a­pies us­ing com­pu­ta­tio­n­al meth­ods. Lead pro­gram NEO-201: cy­tokine mimet­ic (ne­oleukin) to ac­ti­vate im­mune cells for can­cer; first de no­vo pro­tein ther­a­peu­tic ev­er cre­at­ed. [more in­for­ma­tion]
NeuroRx
The Com­pany re­port­ed Phase 2 ef­fi­ca­cy and safe­ty da­ta for NRX-011 in De­cem­ber 2018, suggest­ing po­ten­tial for NRX-101 in main­tain­ing re­mis­sion from sev­er­al bipo­lar de­pres­sion with acute sui­ci­dal idea­tion fol­low­ing an ini­tial sta­bi­l­iza­tion with ke­tamine. [more in­for­ma­tion]
NexImmune, Inc.
Anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing di­rect­ly w tar­get­ed T cells. Mul­ti­ple IND fil­ings exp H1'19. [more in­for­ma­tion]
Oncimmune [ONC:LN] £57 MM MCap
Oncim­mune's pro­pri­e­tary plat­form is un­der­pinned by rapid bio­mark­er dis­cov­ery and a com­pre­hen­sive im­muno­genic pro­tein li­brary of over 8,000 anti­genic pro­teins. [more in­for­ma­tion]
Oncopeptides AB [ONCO:ST] SKr7,217 MM MCap
Melflufen (Yga­lo): alky­lat­ing pep­tide se­lec­tive­ly tar­gets MM; su­pe­ri­or ef­fi­ca­cy vs. SOC. In­ter­im da­ta at EHA (2018) from on­go­ing Ph2 study in late stage r/r MM showed ORR of ~32%. [more in­for­ma­tion]
PAION AG [PAIOF] US$162 MM MCap
Remi­ma­zo­lam: short-act­ing anes­thet­ic. Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US ap­pro­val filed by part­n­er Cos­mo Phar­ma­ceu­ti­cals in June 2019. Ini­ti­at­ed Ph 3 in gen­er­al anes­th­e­sia in EU in Ju­ly 2018, exp com­ple­tion 2019. [more in­for­ma­tion]
PharmaMar SA [PHM:ES]
Rev­enue gen­er­at­ing with marine-de­rived and nov­el MoA on­col­o­gy prod­ucts. 2018 to­tal rev­enues of &eu­ro;162M. Yon­delis (soft tis­sue sar­co­ma and ovarian can­cer) com­mer­cial­ized with di­rect sales-force in EU and part­n­er­ship in US with Janssen. Zep­syre (lur­binecte­din), op­ti­mized ana­log of Yon­delis, re­port­ed pos­i­tive Ph 2 re­sults with NDA sub­mis­sion ex­pect­ed Q4 2019. [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €817 MM MCap
On­ly prod­uct with fu­ture po­ten­tial to be ap­proved for both pro­phy­laxis and treat­ment of at­tacks of HAE. An­nounced pos­i­tive re­sults from a ph2 study of RU­CON­EST in Con­tract-in­duced Nephro­pa­thy for pa­tients re­ceiv­ing elec­tive coro­nary an­giog­ra­phy with or with­out a per­cu­ta­neous coro­nary in­ter­ven­tion (PCI). [more in­for­ma­tion]
Pharvaris
Phar­varis is fo­cused on bring­ing an oral bradykinin B2 re­cep­tor an­ta­g­on­ist to pa­tients for use as an al­ter­na­tive to in­ject­ed ther­a­pies for hered­i­tary an­gioede­ma (HAE) and other B2 re­cep­tor-me­di­at­ed in­di­ca­tions. POC was de­mon­s­trat­ed in a mon­key mod­el and it’s ap­pli­ca­ble to all pa­tients in HAE. [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$261 MM MCap
An­ti­calins (en­gi­neered lipo­calin pro­teins) for re­sp & on­co dis­eas­es. Im­mi­nent da­ta for AZN-part­nered PRS-060 in­haled IL4 for mod-to-se­vere asth­ma. Cash of $128MM in the bank as of March 2019. [more in­for­ma­tion]
Pliant Therapeutics, Inc.
Pliant has de­vel­oped a port­fo­lio of ful­ly-owned de­vel­op­ment can­di­dates fo­cused on in­hibit­ing the TGFb path­way through in­te­grin in­hi­bi­tion. The com­pany’s lead prod­uct can­di­date, PLN-74809 is an oral small-molecule du­al se­lec­tive in­hibi­tor of &al­pha;vß6 and &al­pha;vß1 in­te­grins that is be­ing de­vel­oped in idio­path­ic pul­mo­nary fi­bro­sis (IPF), and pri­mary scle­ros­ing cholan­gi­tis (PSC). [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] US$364 MM MCap
PN-943 oral GI-re­strict­ed al­pha-4-be­ta-7 an­ta­g­on­ist Ph 2 in ul­cer­a­tive coli­tis to be­gin in ear­ly 2020; and PTG-200, part­nered w/ Janssen, oral GI-re­strict­ed IL-23R an­ta­g­on­ist to be­gin Ph 2 Crohn’s dis­ease study in 4Q19. [more in­for­ma­tion]
Protalix BioTherapeutics [PLX] US$31 MM MCap
Lead as­set in mul­ti Ph 3 trials for Fab­ry dis­ease, part­nered glob­al­ly w Chie­si - In­ter­im Ph 3 (PRX-102) da­ta: im­prove­ment in kid­ney func­tion in pts switched from Re­pla­gal®. Ad­dl Ph 2 (in Cys­tic Fi­bro­sis) [more in­for­ma­tion]
Pulse Biosciences, Inc. [PLSE] US$338 MM MCap
Med de­vice: Nano-Pulse Elec­tro-Sig­nal­ing [more in­for­ma­tion]
R2 Dermatology
Di­rec­tor of the Well­man Cen­ter of Pho­tomedicine at Mas­sachusetts Gen­er­al Hos­pi­tal in Bos­ton, a teach­ing af­fili­ate of Har­vard Med­i­cal School; of the Cu­ta­neous Bi­ol­o­gy Re­search Cen­ter in the De­part­ment of Der­ma­tol­o­gy at Mas­sachusetts Gen­er­al Hos­pi­tal; [more in­for­ma­tion]
Regent Pacific [575:HK]
Re­gent Pa­cif­ic is a di­ver­si­fied in­vest­ment group based in Hong Kong cur­rent­ly hold­ing vari­ous cor­po­rate and strate­g­ic in­vest­ments fo­cus­ing on the health­care, well­ness and life sci­ences sec­tors. The Group has a strong track re­cord of in­vest­ments and has re­turned ap­prox­i­mate­ly US$298 mil­lion to share­hold­ers in the 21 years of fi­nan­cial re­port­ing since its ini­tial public of­fer­ing. [more in­for­ma­tion]
Resolve Therapeutics
An im­muno-ther­a­peu­tics com­pany de­vel­op­ing first-in-class, safe, tar­get­ed ther­a­pies for un­derserved au­toim­mune dis­eas­es. [more in­for­ma­tion]
Savara Inc. [SVRA] US$100 MM MCap
Or­phan lung dis­ease; Mol­gradex, Ph 3, in­haled GM-CSF: au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP), Ph 2a: non­tu­ber­cu­lous my­cobac­te­ria (NTM) lung in­fec­tion [more in­for­ma­tion]
Selvita S.A [SLV:WAR]
PIM/FLT3 ki­nase in­hibi­tor in Ph 1/2 in AML (part­nered w Me­nari­ni) and sm molecule se­lec­tive CD­K8 in­hibi­tor for leukemias, lym­pho­mas, and solid tu­mors: Ph 1/2 ini­ti­a­tion exp H1 2019 [more in­for­ma­tion]
Sernova [SEOVF] US$35 MM MCap
Ser­no­va Corp. is a clin­i­cal-stage re­gen­er­a­tive medicine com­pany com­mer­cial­iz­ing prod­ucts which ben­e­fit pa­tients with chron­ic metabolic, neu­ro­log­i­cal and he­ma­to­log­i­cal dis­eas­es with first ther­a­peu­tic ap­pli­ca­tions in di­a­betes and he­mophilia. The com­pany is cur­rent­ly con­duct­ing a PI/II trial in di­a­bet­ic pa­tients with Hy­po­g­lycemia un­aware­ness. [more in­for­ma­tion]
Sol-Gel Technologies Ltd. [SLGL] US$181 MM MCap
Com­mer­cial­iz­ing brand­ed gener­ic top­i­cal drug prod­ucts (skin dis­eas­es). 2 P3 read­outs in 2019: Rosacea: mid-2019; Acne: YE [more in­for­ma­tion]
Sonnet Biotherapeutics, Inc.
Son­net's in­ter­leukin-based can­di­date has been shown to en­hance pK (up to 10 fold) and im­prove tu­mor de­liv­ery with an in­crease in in vi­vo ef­fi­ca­cy (30 fold) as de­mon­s­trat­ed in a mice tu­mor mod­el. The Son­net plat­form de-risks the use of in­ter­leukins by great­ly ex­tend­ing their in vi­vo half-life, while al­so im­prov­ing their spe­ci­fic­i­ty to tu­mor tis­sue. [more in­for­ma­tion]
Stemline Therapeutics, Inc. [STML] US$495 MM MCap
EL­ZON­RIS, tar­get­ed ther­a­py di­rect­ed to IL-3 re­cep­tor (CD123, ap­proved for BPDC; SL-801 an oral small molecule re­v­ersi­ble in­hibi­tor of XPO1 in Ph 1 trial; and SL-701 an im­munother­a­peu­tic that com­plet­ed Ph 2 trial in pts w/2nd line GBM [more in­for­ma­tion]
sterna biologicals
By tar­get­ing tran­scrip­tion fac­tors that play a cen­tral role in reg­u­lat­ing Th1- and Th2-driv­en in­flam­ma­to­ry mech­anisms, the Com­pany’s pro­pri­e­tary DNAzyme-based drug can­di­dates can in­ter­vene with up­stream in­flam­ma­to­ry pro­cess­es to ad­dress re­lat­ed dis­eas­es more ef­fec­tive­ly. Ster­na cur­rent­ly has four pro­grams in phase 2 de­vel­op­ment. [more in­for­ma­tion]
STRATEC Biomedical AG [SBS:FF] €826 MM MCap
Au­to­ma­tion sys­tems and soft­ware for di­ag­nos­tics in­dus­try. In­s­talled base of >13,000 sys­tems across 20 fam­i­lies in­clud­ing PAN­THER (Ho­log­ic), Li­a­son XL (Di­a­Sorin), VI­DAS (BioMerieux) and AD­VIA (Sie­mens). Rev gen­er­at­ing and pro­f­itable; growth drivers in­cl prod­uct launch­es/ramp-ups, new tests; de­mo­graph­ics and out­sourc­ing in IVD in­dus­try. [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] US$148 MM MCap
Rare dis­eas­es; Keveyis for PPP 2019 rev­enue gui­dance of $18-20M; Re­cor­lev 2nd Phase 3 top-line re­sults 1Q 2020; NDA sub­mis­sion exp 3Q 2020 [more in­for­ma­tion]
Sutro Biopharma [STRO] US$243 MM MCap
Fo­cused on de­vel­op­ing next gen­er­a­tion anti­body drug con­ju­gates (ADCs) and mul­ti-spe­cif­ic anti­body-based ther­a­peu­tics for can­cer ther­a­py. STRO-001 for mul­ti­ple myelo­ma and lym­pho­mas is in Ph 1 and ex­pects ini­tial safe­ty da­ta in mid-2019. IND sub­mis­sion for STRO-002 for ovarian and en­dome­trial can­cer in Q4 2018 with the ini­ti­a­tion of a Ph 1 trial planned for ear­ly 2019. [more in­for­ma­tion]
Syneos Health [SYNH] US$5,696 MM MCap
On­ly ful­ly in­te­grat­ed bio­phar­ma­ceu­ti­cal so­lu­tions or­gani­za­tion in­cl CRO and Con­tract Com­mer­cial Or­gani­za­tion (CCO)/ (merg­er of INC Re­search & in­Ven­tiv) [more in­for­ma­tion]
Targovax [TRVX:OS] NKr333 MM MCap
On­co­lyt­ic ade­n­ovirus armed w im­mune sti­m­u­lat­ing trans­gene tar­get­ing bas­ket of I-O in­di­ca­tions. Strong re­sults from Part 1 (ON­COS-102/Keytru­da com­bo) trial in an­ti-PD1 re­frac­to­ry me­lano­ma: 33% ORR in 9 pts: 1 CR, 2 PRs; im­mune ac­ti­va­tion de­mon­s­trat­ed in all 9 pts. Jan 2020: exp ran­domized da­ta, Ph 1b/ 2 (me­sothe­lio­ma, n=31) w/che­mo [more in­for­ma­tion]
Tessa Therapeutics
On­go­ing Ph III – (na­sopha­ryn­geal can­cer), Ph I – (cer­vi­cal, mov­ing in­to Ph II); mul­ti­ple other as­sets en­ter­ing clin­ic. Key col­labs: Bay­lor, Park­er Inst, St. Jude Chil­dren’s [more in­for­ma­tion]
Trio Health
Strives to col­lect and an­a­lyze re­al world evi­dence that may be used to im­prove the qual­i­ty of health care avai­l­able to all pa­tients. Trio has de­vel­oped a pro­pri­e­tary tech­nol­o­gy plat­form that re­defines the ap­proach and metho­d­ol­o­gy of col­lect­ing ret­ro­spec­tive ob­ser­va­tio­n­al da­ta on re­al world pa­tients. [more in­for­ma­tion]
Vaccitech Limited
T cell im­munother­a­pies for in­fec­tious dis­eas­es (ID) and can­cer via CD8+ T cell in­duc­tion – spi­nout from Jen­n­er In­sti­tute. ChA­dOx (prime) and MVA (boost) pipe­line in­clud­ing piv­o­tal Ph2b for flu pro­phy­lac­tic in Q1 2020 and Ph1/2 POC for HPV and HBV im­munother­a­pies by Q1 2021, two can­cer im­munother­a­py pro­grams (per­so­n­al­ized vaccine and MAGE-NYE­SO ther­a­peu­tics) en­ter­ing clin­ic in 2020. [more in­for­ma­tion]
Valbiotis [AVAL-FR]
De­vel­op­ing pro­pri­e­tary plant-de­rived bio­molecules to pre­vent metabolic dis­eas­es. Lead pro­gram VALE­DIA®, tar­get­ing the un­ad­dressed pre­di­a­betes mar­ket, re­cent­ly re­port­ed pos­i­tive Ph 2a da­ta for pre­di­a­betes. VALE­DIA® sig­ni­f­i­cant­ly re­duced fast­ing blood glu­cose lev­els, com­pared to the place­bo, af­ter 6 months (p [more in­for­ma­tion]
Vericel Corporation [VCEL] US$709 MM MCap
Ad­vanced cell ther­a­py; mar­ket­ing MA­CI (car­ti­lage re­pair) and Epi­cel (skin re­place­mentt) in TAMs of $2b+. Re­cent­ly ac­quired US com­mer­cial rights for Nexo­Brid. [more in­for­ma­tion]
Verrica Pharmaceuticals [VRCA] US$372 MM MCap
is an in­no­va­tive clin­i­cal-stage med­i­cal der­ma­tol­o­gy com­pany com­mitt­ed to iden­ti­fy­ing, de­vel­op­ing, and com­mer­cial­iz­ing nov­el phar­ma­ceu­ti­cal prod­ucts for the treat­ment of skin dis­eas­es and con­di­tions with sig­ni­f­i­cant un­met needs. [more in­for­ma­tion]
Viela Bio
Lead pro­gram, Ine­bi­l­izumab, is a CD19 mAb which met the pri­mary end­point in the Ph 2b piv­o­tal study for the treat­ment of Neu­romyeli­tis Op­ti­ca. Pri­mary anal­y­sis de­mon­s­trat­ed a 77% re­duc­tion in the risk of de­vel­op­ing NMOSD at­tack in pa­tients treat­ed with ine­bi­l­izumab monother­a­py com­pared to place­bo. [more in­for­ma­tion]
vTv Therapeutics, Inc. [VTVT] US$90 MM MCap
June 2019 pos­i­tive da­ta for TT­P399 as an add-on ther­a­py to in­sulin ther­a­py in a 12 week phase 1/2 trial in pa­tients with T1D. Re­cent­ly an­nounced the first pa­tient has been screened for the Ph2 proof of con­cept study eval­u­at­ing the safe­ty and ef­fi­ca­cy of azeli­ra­gon in pa­tients with mild Alzheimer's dis­ease and Type 2 Di­a­betes. [more in­for­ma­tion]
Yisheng Biopharma
Prod­ucts in de­vt in­clude YS-ON-001 (Ph 1), an IO prod­uct tar­get­ing solid tu­mors and new gen of bi­o­log­ics for pre­ven­tive and ther­a­peu­tic ben­e­fits, in­cl YS-HBV-001 (Ph 1) and PI­KA ra­bies vaccine (Ph 3), tar­get­ing hep B and ra­bies in­fec­tions. GMP cer­ti­fi­ca­tion re­ceived Ju­ly 2019 for Ju­nan, the first med­i­cal freeze-dried ra­bies vaccine with­out an alu­minum ad­ju­vant pro­duced in Chi­na. [more in­for­ma­tion]